Catalyst Repository | Inozyme Pharma Inc. Common Stock

Inozyme Pharma Inc. Common Stock

(NASDAQ:INZY)

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

INZY Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$6.9200
Previous Close Volume
627390